US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

GILD Gilead Sciences Inc

92.56

1.47 (1.61%)

20 Dic 2024 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/26/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Jeffrey Bluestone

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Gilead Sciences (NASDAQ:GILD)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Haga Click aquí para más Gráficas Gilead Sciences.

Gilead Sciences (NASDAQ:GILD)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024

Haga Click aquí para más Gráficas Gilead Sciences.

Noticias sobre Gilead Sciences Inc GILD

Gilead Sciences to Present at Upcoming Investor Conference
Viernes 20 de Diciembre 2024 (2 días hace) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Jueves 19 de Diciembre 2024 (3 días hace) • Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Jueves 19 de Diciembre 2024 (3 días hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martes 17 de Diciembre 2024 (5 días hace) • Edgar (US Regulatory)

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Martes 17 de Diciembre 2024 (5 días hace) • Business Wire

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Martes 17 de Diciembre 2024 (5 días hace) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 16 de Diciembre 2024 (6 días hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Lunes 16 de Diciembre 2024 (6 días hace) • Edgar (US Regulatory)

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Viernes 13 de Diciembre 2024 (1 semana hace) • Business Wire

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Jueves 12 de Diciembre 2024 (1 semana hace) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 11 de Diciembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 11 de Diciembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Más de Gilead Sciences Inc Artículos de Noticias

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones